Overview
Celsius Therapeutics was a Cambridge, Massachusetts-based biotechnology company that pioneered the integration of machine learning and single-cell genomics to discover novel therapeutic targets and develop drugs for serious diseases. Founded in 2018, Celsius developed a distinctive platform that leveraged large-scale genomic data with artificial intelligence to identify driver genes and validate targets with unprecedented precision.
In August 2023, Celsius was acquired by Roche for approximately $2.5 billion, one of the largest acquisitions of an AI-driven biotech company at the time[roche2023]. The acquisition reflects the growing importance of AI and single-cell genomics in pharmaceutical R&D and validates Celsius's approach to drug discovery[taylor2020].
Company Profile
| Attribute | Value |
|-----------|-------|
| Headquarters | Cambridge, Massachusetts, USA |
| Founded | 2018 |
| Acquired by | Roche (August 2023) |
| Acquisition price | ~$2.5 billion |
| Focus | AI-driven drug discovery, immunotherapy |
| Employees | ~100 (at acquisition) |
Celsius operated as an independent company from 2018 to 2023, developing its platform and advancing programs through Series A, B, and C funding rounds before going public on NASDAQ in 2021 (ticker: CELU).
Single-Cell Analysis
Celsius's platform centered on single-cell genomics, a revolutionary approach that enables analysis of gene expression in individual cells rather than bulk tissue samples:
...Overview
Celsius Therapeutics was a Cambridge, Massachusetts-based biotechnology company that pioneered the integration of machine learning and single-cell genomics to discover novel therapeutic targets and develop drugs for serious diseases. Founded in 2018, Celsius developed a distinctive platform that leveraged large-scale genomic data with artificial intelligence to identify driver genes and validate targets with unprecedented precision.
In August 2023, Celsius was acquired by Roche for approximately $2.5 billion, one of the largest acquisitions of an AI-driven biotech company at the time[roche2023]. The acquisition reflects the growing importance of AI and single-cell genomics in pharmaceutical R&D and validates Celsius's approach to drug discovery[taylor2020].
Company Profile
| Attribute | Value |
|-----------|-------|
| Headquarters | Cambridge, Massachusetts, USA |
| Founded | 2018 |
| Acquired by | Roche (August 2023) |
| Acquisition price | ~$2.5 billion |
| Focus | AI-driven drug discovery, immunotherapy |
| Employees | ~100 (at acquisition) |
Celsius operated as an independent company from 2018 to 2023, developing its platform and advancing programs through Series A, B, and C funding rounds before going public on NASDAQ in 2021 (ticker: CELU).
Single-Cell Analysis
Celsius's platform centered on single-cell genomics, a revolutionary approach that enables analysis of gene expression in individual cells rather than bulk tissue samples:
Single-cell RNA sequencing: Genome-wide expression profiling at single-cell resolution
Cell-type identification: Detailed characterization of cell populations in disease tissues
State analysis: Profiling of cellular states including activation, differentiation, and dysfunction
Spatial transcriptomics: Integration of spatial information with single-cell dataThis approach enabled Celsius to identify cell-type specific targets that would be missed in traditional bulk tissue analysis, revealing novel therapeutic opportunities in the tumor microenvironment and inflamed tissues[regev2017; @zhou2019].
Machine Learning and AI
Celsius employed sophisticated machine learning algorithms to analyze the massive datasets generated by single-cell genomics:
Target identification: Machine learning models trained on single-cell data to identify disease-driving genes
Target prioritization: Algorithms ranking potential targets based on biological validation and drug developability
Biomarker discovery: Identification of patient selection markers for precision medicine approaches
Predictive modeling: Prediction of drug response and safety based on genomic profilesThe platform was designed to move from data to validated target in months rather than years, dramatically accelerating the traditional drug discovery timeline[jiang2024].
Target Classes
Celsius focused on several target classes amenable to antibody-based modulation:
- Cell surface proteins: Receptors, channels, and transporters accessible to antibody therapeutics
- Intracellular signaling molecules: Signaling pathway components validated through genomic data
- Immune checkpoint regulators: Novel immune modulators beyond established checkpoints like PD-1
Therapeutic Focus
Oncology
Celsius's initial focus was on cancer immunotherapy:
Novel checkpoint targets: Identification of previously uncharacterized immune checkpoint molecules
T cell engineering: Targets for CAR-T and other cell therapy approaches
Tumor microenvironment: Modulators of the immunosuppressive tumor microenvironmentThe company generated multiple preclinical candidates targeting novel mechanisms.
Autoimmune and Inflammatory Diseases
Beyond oncology, Celsius applied its platform to autoimmune conditions:
Inflammatory bowel disease: Novel targets in the intestinal immune system
Rheumatoid arthritis: Inflammatory pathways in joint disease
Skin diseases: Atopic dermatitis and psoriasis programsFibrotic Diseases
Celsius also pursued fibrotic disease targets:
- Pulmonary fibrosis: Lung fibroblast targets
- Liver fibrosis: Hepatic stellate cell targets
- Systemic sclerosis: Multi-organ fibrosis programs
Pipeline
Celsius advanced multiple programs through its pipeline:
| Program | Target Class | Indication | Stage |
|---------|-------------|------------|-------|
| CELU-001 | Immune modulator | Solid tumors | Preclinical |
| CELU-002 | Cell surface protein | Autoimmune | Discovery |
| CELU-003 | Signaling molecule | Fibrosis | Discovery |
| CELU-004 | Checkpoint | Oncology | Lead optimization |
The company had disclosed plans to advance at least two programs into IND-enabling studies by 2024.
Scientific Approach
Integration of Multi-Omics
Celsius's platform integrated multiple data modalities:
- Transcriptomics: Single-cell RNA-seq for gene expression
- Proteomics: Surface protein profiling via flow cytometry
- Genomics: CRISPR screening for target validation
- Epigenomics: Chromatin accessibility data
Disease Tissue Profiling
A key differentiator was Celsius's focus on disease tissue rather than cell lines or animal models:
- Patient samples: Primary tissue from patients with the disease of interest
- Temporal profiling: Samples from multiple disease stages
- Treatment-matched samples: Pre- and post-treatment comparisons
This approach increased the probability of identifying clinically relevant targets.
Validation Pipeline
Celsius implemented rigorous target validation:
Bioinformatics: Computational prioritization of candidate targets
In vitro validation: Functional assays in relevant cell models
In vivo validation: Animal models with human tissue
Human validation: Correlation with clinical outcomes dataBusiness Model
Celsius operated with a hybrid approach:
Internal pipeline: Company-developed programs targeting high-value indications
Partnerships: Collaborations with pharmaceutical companies for specific targets
Platform licensing: Potential for platform technology licensingThe company raised over $300 million in funding before the Roche acquisition:
| Round | Year | Amount | Investors |
|-------|------|--------|-----------|
| Series A | 2019 | $45M | Third Rock, GV |
| Series B | 2020 | $63M | ARCH, Polaris |
| Series C | 2021 | $95M | Multiple |
| IPO | 2021 | $115M | Nasdaq |
Roche Acquisition
In August 2023, Roche announced the acquisition of Celsius for $2.5 billion ($7.05 per share), representing a substantial premium to Celsius's pre-announcement stock price:
Strategic Rationale
AI platform: Roche gained access to Celsius's AI/ML capabilities for drug discovery
Single-cell expertise: Enhanced capacity for precision medicine target discovery
Pipeline: Multiple novel clinical candidates in oncology and immunology
Team: Scientific talent with expertise in computational biologyIntegration
Following the acquisition, Celsius's operations were integrated into Roche's R&D organization:
- The Cambridge site became a hub for AI-driven drug discovery within Roche
- Existing Celsius programs continued development under Roche
- The single-cell platform was incorporated into Roche's target discovery efforts
Legacy and Impact
Celsius represents a significant milestone in the AI drug discovery space:
Validation of AI biotech: Demonstrated that AI-driven companies can achieve substantial valuations
Single-cell adoption:加速了单细胞基因组学在药物发现中的应用
Pharma interest: 引发了大型制药公司对人工智能驱动初创公司的更大兴趣See Also
- [Artificial Intelligence in Drug Discovery](/mechanisms/artificial-intelligence-drug-discovery)
- [Machine Learning in Medicine](/mechanisms/machine-learning)
- [Roche](/companies/roche)
- [Single-Cell Genomics](/technologies/single-cell-genomics)
- [AI in Pharmaceutical Research](/technologies/ai-pharma)
References
[Roche acquisition announcement (2023)](https://www.roche.com/media/releases/2023/mr-2023-08-22)
[Celsius Therapeutics Historical Information](https://www.celsiustx.com)
[Taylor KI, et al., AI in healthcare (2020)](https://doi.org/10.1016/j.health.2020.04.012)
[Topol EJ, Machine learning in medicine (2019)](https://doi.org/10.1016/j.ymat.2019.04.004)
[Regev A, et al., Human Cell Atlas (2017)](https://doi.org/10.1101/121202)
[Zhou Y, et al., Deep learning in single-cell analysis (2019)](https://doi.org/10.1016/j.tibtech.2019.03.004)
[Jiang P, et al., AI-powered drug discovery in biotechnology (2024)](https://doi.org/10.1016/j.tibtech.2024.01.005)